Abeona acquires EoE drug candidate ABO-801 from Ellodi, plans $30 million private placement

Abeona Therapeutics announced on November 9, 2026 that it had acquired APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals, L.P. Abeona Therapeutics Inc. announced the acquisition of APT-1011 (now ABO-801), a product candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals, and entered into a securities purchase agreement for a $30 million private placement financing.¹ The deal closed November 6, 2026.

ABO-801 is a once-daily oral disintegrating tablet formulation of fluticasone propionate being developed for EoE, a chronic inflammatory disease of the esophagus characterized by symptoms including difficulty swallowing and food impaction.¹ The company said approximately 360,000 patients in the United States have been diagnosed with EoE.¹ The candidate carries Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of EoE.¹

On the clinical record, the companies said the program has run through a 24-patient Phase 1/2a trial, a 106-patient Phase 2b dose-ranging study, and two completed Phase 3 studies that enrolled a combined 361 patients, with additional longer-term treatment experience through an Expanded Access Program involving 265 cumulative participants.¹ Neither prior Phase 3 trial hit its symptom goal: although neither Phase 3 study met its prespecified co-primary patient-reported symptom endpoint, both demonstrated statistically significant improvements in several endoscopic measures and yielded important insights that are informing the design of a planned future Phase 3 study.¹ Abeona said it expects to start that new Phase 3 study in the second quarter of 2027, with topline data anticipated by the end of 2028, subject to the timing of study initiation and enrollment.¹

Under the asset purchase agreement, Abeona issued Ellodi $20 million in value of common stock, amounting to 4,494,383 shares, based on the 20-trading-day volume weighted average price ending the day before closing, with no upfront cash consideration.¹ Ellodi also stands to receive payments of $30 million upon FDA approval of a New Drug Application for APT-1011 and up to $30 million upon achievement of certain sales milestones, plus royalty payments on net sales with tiers ranging from low to mid teen percentages.¹

Separately, Abeona priced a private placement of 6,400,000 shares of common stock at $3.75 per share and pre-funded warrants for up to 1,600,043 shares at $3.7499 per warrant, expected to generate $30 million in gross proceeds before fees.¹ The closing is expected November 10, 2026. Proceeds are intended for pipeline development and to support ZEVASKYN commercialization, the company said.